SM 16

Key Product Details

Product Description

SM 16 is a potent TGF-β receptor type 1 (TGF-βRI) inhibitor (IC₅₀ = 64 nM in luciferase assay). Selective for TGF-βRI over other ALK family members. Decreases Smad phosphorylation and inhibits tumor growth in a mouse xenograft model. Attenuates increased TGF-β signaling in retinal vessels of diabetic rats. Also prevents intimal thickening and vascular remodeling in rat carotid balloon injury model. Orally bioavailable.

Product Specifications for SM 16

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SM 16

The following data is based on the product molecular weight 430.50.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.32 mL	11.61 mL	23.23 mL
5 mM	0.46 mL	2.32 mL	4.65 mL
10 mM	0.23 mL	1.16 mL	2.32 mL
50 mM	0.05 mL	0.23 mL	0.46 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Fu SM16, an orally active TGF-β type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler.Thromb.Vasc.Biol. 2008 PMID: 18202322
• Dagher The increased transforming growth factor-β signaling induced by diabetes protects retinal vessels. Am.J.Pathol. 2017 PMID: 28162229
• Suzuki A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 2007 PMID: 17332368

Product Documents for SM 16